CDX2 and malignant colon neoplasm: The Sidra-LUMC AC-ICAM cohort contained a lower percentage of colon cancers with CDX2 suppression (6%, 21 of 348 cases) and a higher percentage of non-CDX2-suppressed cases (62.9%, 219 of 348 cases) than TCGA.